BAY 2416964

Cat. No.: HY-135829

CAS No.: 2242464-44-2

Molecular Formula: $C_{18}H_{18}ClN_5O_3$

Molecular Weight: 387.82

Target: Aryl Hydrocarbon Receptor

Pathway: Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (128.93 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5785 mL	12.8926 mL	25.7852 mL
5 mM	0.5157 mL	2.5785 mL	5.1570 mL
10 mM	0.2579 mL	1.2893 mL	2.5785 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (6.45 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 192, has an IC_{50} of 341 nM. BAY 2416964 has the potential for solid tumors treatment[1].

IC_{50} & Target

IC50: 341 nM (Aryl hydrocarbon receptor (AHR))[1]

In Vitro

BAY 2416964 (Example 192) induces AHR-regulated gene CYP1A1 expression in a human monocytic U937 cells with an IC_{50} of 4.3 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA